TrialPediatric blood & cancer2014

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Nathan J Robison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.